US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Attovia Therapeutics / Equity Capital Markets

<ul>
<li>Clinical-Stage biotech leveraging the proprietary ATTOBODY platform, with lead candidate ATTO-1310 completing Phase 1 and two additional pipeline programs advancing toward the clinic.</li>
<li>Seeking approximately $182 million to fund clinical development, expand its pipeline, and support operations as it advances multiple immune-mediated disease programs.</li>
<li>Early-Stage, Phase 1 IPO backed by Frazier Life Sciences and licensed from Alamar Biosciences, making institutional demand likely to be the key trading catalyst.</li>
</ul>


Clinical-Stage biotech leveraging the proprietary ATTOBODY platform, with lead candidate ATTO-1310 completing Phase 1 and two additional pipeline programs advancing toward the clinic.
Seeking approximately $182 million to fund clinical development, expand its pipeline, and support operations as it advances multiple immune-mediated disease programs.
Early-Stage, Phase 1 IPO backed by Frazier Life Sciences and licensed from Alamar Biosciences, making institutional demand likely to be the key trading catalyst.


Attovia Therapeutics (ATTO): Phase 1 Immune Therapy Biotech Sets Terms for IPO

<ul>
<li>Avalyn Pharma Inc. prices IPO at $16–$18/share, offering 11.8M shares to fund inhaled fibrosis therapies, targeting ~$591M–$665M valuation.</li>
<li>Clinical-Stage pipeline led by AP01 and AP02 aims to treat IPF and PPF via inhaled antifibrotics, addressing high unmet need in interstitial lung disease.</li>
<li>Backed by top-tier underwriters including Morgan Stanley and Jefferies; CEO Lyn Baranowski brings deep respiratory biotech experience and strong M&amp;A track record.</li>
</ul>


Avalyn Pharma Inc. prices IPO at $16–$18/share, offering 11.8M shares to fund inhaled fibrosis therapies, targeting ~$591M–$665M valuation.
Clinical-Stage pipeline led by AP01 and AP02 aims to treat IPF and PPF via inhaled antifibrotics, addressing high unmet need in interstitial lung disease.
Backed by top-tier underwriters including Morgan Stanley and Jefferies; CEO Lyn Baranowski brings deep respiratory biotech experience and strong M&amp;A track record.


Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>Friday’s IPO slate — Aevex Corp. (AVEX), Alamar Biosciences (ALMR), and Kailera Therapeutics (KLRA) — delivered a constructive signal for the broader IPO market, with all three names opening at strong double-digit premiums to their respective IPO prices.</li><li>As the first meaningful cluster of deals to come to market in recent weeks, the group sets an early tone for sentiment, with a growing pipeline behind it including Yesway Inc., National Healthcare Properties, The Elmet Group, and X-Energy Inc., all expected to trade the week of 4/20.</li><li>Aevex (AVEX) opened at $23.01 versus a $20.00 IPO price, representing a ~15% premium out of the gate and immediately confirming early demand with a Bull signal at the open.</li></ul>

Friday’s IPO slate — Aevex Corp. (AVEX), Alamar Biosciences (ALMR), and Kailera Therapeutics (KLRA) — delivered a constructive signal for the broader IPO market, with all three names opening at strong double-digit premiums to their respective IPO prices.As the first meaningful cluster of deals to come to market in recent weeks, the group sets an early tone for sentiment, with a growing pipeline behind it including Yesway Inc., National Healthcare Properties, The Elmet Group, and X-Energy Inc., all expected to trade the week of 4/20.Aevex (AVEX) opened at $23.01 versus a $20.00 IPO price, representing a ~15% premium out of the gate and immediately confirming early demand with a Bull signal at the open.

IPO Class Opens With Strong Double-Digit Premiums as Follow-Through Proves Mixed

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alamar Biosciences (ALMR US)

Attovia Therapeutics (ATTO): Phase 1 Immune Therapy Biotech Sets Terms for IPO

Clinical-Stage biotech with ATTOBODY platform seeks funding for immune-mediated disease programs, including lead candidate ATTO-1310. Early-Stage...

IPO Boutique

Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

Avalyn Pharma Inc. prices IPO to fund inhaled fibrosis therapies, targeting high valuation; clinical-stage pipeline aims to treat IPF and PPF with...

IPO Boutique

IPO Class Opens With Strong Double-Digit Premiums as Follow-Through Proves Mixed

Friday’s IPO slate — Aevex Corp. (AVEX), Alamar Biosciences (ALMR), and Kailera Therapeutics (KLRA) — delivered a constructive signal for the...

IPO Prophet

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Attovia Therapeutics (ATTO): Phase 1 Immune Therapy Biotech Sets Terms for IPO

​Clinical-Stage biotech with ATTOBODY platform seeks funding for immune-mediated disease programs, including lead candidate ATTO-1310. Early-Stage...

IPO Boutique

Avalyn Pharma (AVLN): Phase 2 Biotech for Treatment of Pulmonary Fibrosis Sets Terms for IPO

​Avalyn Pharma Inc. prices IPO to fund inhaled fibrosis therapies, targeting high valuation; clinical-stage pipeline aims to treat IPF and PPF with...

IPO Boutique

IPO Class Opens With Strong Double-Digit Premiums as Follow-Through Proves Mixed

Friday’s IPO slate — Aevex Corp. (AVEX), Alamar Biosciences (ALMR), and Kailera Therapeutics (KLRA) — delivered a constructive signal for the...

IPO Prophet

Clinical-Stage biotech with ATTOBODY platform seeks funding for immune-mediated disease programs, including lead candidate ATTO-1310. Early-Stage...

Avalyn Pharma Inc. prices IPO to fund inhaled fibrosis therapies, targeting high valuation; clinical-stage pipeline aims to treat IPF and PPF with...